Economic Growth Overview - In November 2025, China's industrial added value grew by 4.8% year-on-year, slightly down by 0.1 percentage points from the previous month[3] - The service production index increased by 4.2% year-on-year, a decrease of 0.4 percentage points compared to October[3] - Retail sales of consumer goods rose by 1.3% year-on-year, down 1.6 percentage points from the previous month[3] Sector Performance - High-tech manufacturing added value increased by 8.4%, accelerating by 1.2 percentage points from the previous month, outpacing the overall industrial growth rate by 3.6 percentage points[3] - The export delivery value showed a marginal recovery, with a year-on-year decline of 0.1%, improving by 2.0 percentage points from October[3] - The service retail sales grew by 5.4% year-on-year from January to November, with a 0.1 percentage point increase compared to the previous month[3] Investment Trends - Fixed asset investment saw a cumulative year-on-year decline of 2.6% from January to November, a drop of 0.9 percentage points from the previous month[3] - Infrastructure and manufacturing investments maintained expansion, with cumulative year-on-year growth rates of 0.1% and 1.9%, respectively[3] - Equipment purchase investment rose by 12.2% year-on-year, contributing 1.8 percentage points to overall investment growth[3] Risks and Outlook - Risks include potential underperformance of growth stabilization policies, unexpected severity of overseas economic downturns, and escalation of geopolitical conflicts[3]

Core Viewpoints - The report emphasizes the importance of improving efficiency and optimizing the industry structure in the securities sector, projecting a strong performance relative to the market for 2026 [1] Market Review - The securities sector has demonstrated a prominent Beta attribute, with significant attention on the shift in funding styles. Historical analysis indicates that periods of excess returns for brokerages typically require a confluence of policy, liquidity, and market conditions [4][9] - From January to November 2025, the securities index underperformed the CSI 300 index by 12.9 percentage points, attributed to factors such as technology style preferences and the diversion of funds towards low-valuation H-shares [4][43] - Despite this, the brokerage sector achieved a notable excess return from April to August 2025, particularly H-share brokerages, which saw a cumulative increase of 43.9% for the year, outperforming the CSI 300 index by 25.4 percentage points [4][43] Fundamental Outlook - The equity market is experiencing high prosperity, with a strong certainty of profit growth. In the first three quarters of 2025, listed brokerages reported a year-on-year net profit growth of 63.4% and a revenue increase of 13.0% [4][20] - The revenue structure for the first three quarters of 2025 shows significant growth in brokerage, investment banking, and proprietary trading, with net income growth rates of 68%, 16%, and 42% respectively [4][20] - The wealth management sector is positioned to capitalize on internationalization trends, with Hong Kong emerging as a preferred fundraising destination for Chinese enterprises, leading to a 146% increase in IPO fundraising compared to the entire year of 2024 [4][20] Investment Recommendations - The report suggests that as capital market reforms deepen, the securities industry is expected to maintain steady growth in 2026, benefiting particularly head brokerages through mergers and acquisitions [4][20] - Recommended stocks include CITIC Securities and CICC, which are expected to benefit from their strong comprehensive service capabilities and balanced business structures [4][20] - Other notable mentions include Guosen Securities, Industrial Securities, and Dongfang Securities, which are anticipated to perform well due to their advantages in financial products and services [4][20] Valuation Insights - The current price-to-book (P/B) ratio for the securities industry stands at 1.35x, which is below the historical average of 1.71x, indicating potential for valuation recovery [4][50] - The report highlights that the industry P/B valuation is at the 27.7% historical percentile, suggesting that there is room for improvement in valuations relative to historical performance [4][50]

Report Industry Investment Rating No relevant information provided. Report Core View - As of the end of November 2025, there were 469 fund investment advisor portfolios on the Tiantian Fund APP, an increase of 4 from the end of the previous month. Among them, there were 2 new balanced, 1 new aggressive, and 1 new consumer-themed portfolio [2][8]. - In terms of performance, over the past year, the median returns of aggressive and balanced portfolios outperformed similar FOF products, while the median return of the stable portfolio underperformed. In November, the median returns of aggressive, balanced, and stable portfolios outperformed both similar FOF products and their benchmarks. Among the track-type portfolios, only the gold track had a positive median return in November. For the regional portfolios, both the Hong Kong stock strategy and overseas strategy portfolios had median returns that underperformed their benchmarks in November [2][17][24]. - Regarding position changes, stable portfolios reduced bond funds and increased QDII funds; balanced portfolios reduced bond funds and increased money market funds; aggressive portfolios reduced hybrid funds and increased QDII funds. In terms of individual fund positions, consumer-themed, small-cap strategy, and real estate-themed funds were significantly increased [2][33][42]. - In November 2025, there were 91 portfolio adjustments, an increase of 1 from the previous month. Stable portfolios increased commodity funds and reduced active bond funds; balanced portfolios increased fixed-income + funds and reduced QDII funds; aggressive portfolios increased passive equity funds and reduced QDII funds [2][65]. Summary by Directory Fund Investment Advisor Portfolio Overall Situation - **Portfolio Structure**: As of the end of November 2025, there were 412 stock-bond central, 36 track-type, and 21 regional investment advisor portfolios. The number of stock-bond central portfolios dominated, with the aggressive type being the most numerous among them. Track-type portfolios were concentrated in growth industries, and regional portfolios mainly targeted global overseas markets including Hong Kong and US stocks [8]. - **Investment Advisor Institution Distribution**: Institutions such as Huabao Securities, Guolian Securities, Southern Fund, and Zhongou Fortune had a relatively large number of portfolios on the platform. The top ten institutions accounted for 66% of the total. Most of the portfolios were established between February and May 2022, with 2 new portfolios launched in November 2025 [12]. Investment Advisor Portfolio Performance Tracking - **Stock-Bond Central Investment Advisor Portfolio Performance**: Over the past year, the median returns of aggressive and balanced portfolios outperformed similar FOF products, while the stable portfolio underperformed. In November, all three types outperformed similar FOF products. Compared with the benchmark, the median returns of aggressive portfolios underperformed the benchmark over the past year, while the other three types outperformed. In November, all three types outperformed the benchmark. The Anxin Aggressive 90 of Guolian Securities, Taoli Buyan of Guolian Securities, and Shendu Stable of Shenwan Hongyuan Fund had the highest returns this year. The Huaxia All-Weather Multi-Aggressive Allocation of Huaxia Fortune, Zhongou Multi-All-Weather of Zhongou Fortune, and China Merchants Spare Money Best of China Merchants Fund had the highest Sharpe ratios this year [16][17][21]. - **Track-Type and Regional Investment Advisor Portfolio Performance**: Over the past year, all track-type portfolios had positive median returns, with most outperforming the benchmark except for the intelligent manufacturing and gold tracks. In November, only the gold track had a positive median return, and several tracks outperformed the benchmark. For regional portfolios, the Hong Kong stock strategy portfolio outperformed the benchmark over the past year, while both the Hong Kong stock strategy and overseas strategy portfolios underperformed in November. The top-performing track-type portfolios this year were mainly in the medical and technology sectors, and the top-performing regional portfolios were mainly in the Hong Kong stock strategy, with some overseas strategy portfolios also performing well [23][24][28]. Investment Advisor Portfolio Position Adjustment Tracking - **Holding Fund Position Change Tracking**: When analyzing the position changes of 449 portfolios, stable portfolios decreased bond funds and increased QDII funds; balanced portfolios decreased bond funds and increased money market funds; aggressive portfolios decreased hybrid funds and increased QDII funds. Among the 77 portfolios that disclosed individual fund positions, stable portfolios decreased active bond funds and increased fixed-income + funds; balanced portfolios decreased active bond funds and increased money market funds; aggressive portfolios decreased quantitative funds and increased passive equity funds [33][36]. - **Investment Advisor Portfolio Individual Fund Holding Tracking**: - **Active Equity Funds**: Value-style, quantitative strategy, dividend strategy, and technology-themed fund managers were favored. Consumer-themed, small-cap strategy, and real estate-themed funds were significantly increased [38][42]. - **QDII Funds**: Products such as Southern Asia US Dollar Bond A RMB, Huaxia Hang Seng Technology ETF Link A, and Tianhong S&P 500 A were favored. Global allocation products like Huatai-PineBridge Global Medical RMB and China Merchants Pusu Global Allocation A, as well as products tracking the Hang Seng Technology Index in the Hong Kong market, were significantly increased [43][47]. - **Passive Index Funds**: Dividend low-volatility strategy index funds and industry index funds such as Hong Kong Stock Connect Internet, gold stocks, liquor, and chemicals were favored. Industry-themed index products such as banks, coal, and gold stocks were significantly increased [49][52]. - **Fixed-Income + Funds**: Products such as Invesco Great Wall Jingyi Double Dividend, Zhongou Jintong, and Yongying Stable Enhancement were favored. Products such as China Merchants Anben Zengli and Huatai-PineBridge Zunli were significantly increased [54][57]. - **Active Bond Funds**: Products managed by fund managers such as Wang Xiaochen, Wang Shuai, Fang Chang, Song Qianqian, and Ji Lingyun were favored. Products such as Zhongou Pure Bond and Fullgoal Short Bond were significantly increased [59][62]. - **Fund Investment Advisor Position Adjustment Situation Tracking**: In November 2025, there were 91 portfolio adjustments, mainly in aggressive and stable portfolios. Stable portfolios increased commodity funds and reduced active bond funds; balanced portfolios increased fixed-income + funds and reduced QDII funds; aggressive portfolios increased passive equity funds and reduced QDII funds. A total of 13 funds had a net increase of 5 or more investment advisor portfolios, including 3 active equity funds, 4 passive equity funds, 2 active bond funds, 3 QDII funds, and 1 commodity fund [65][70].

Core Insights - The report emphasizes the continuous improvement of the global competitiveness of Chinese innovative pharmaceutical companies, focusing on innovation from both "therapeutic areas" and "technology platforms" [5][6] - The growth of commercial health insurance premiums is expected to provide new payment sources for medical expenses, as the scale of commercial health insurance is projected to reach 977.4 billion yuan by 2024 [29][30] - The report identifies potential therapeutic areas such as metabolic diseases (e.g., weight loss), chronic diseases (e.g., hypertension, hyperlipidemia), and central nervous system diseases (e.g., Alzheimer's, Parkinson's) as key focus areas for innovation [5][38] - Emerging technology platforms like small nucleic acid drugs, radioactive drugs (RDC), and CAR-T therapies are highlighted as significant areas for investment [5][38] Market Review - As of November 15, 2025, the pharmaceutical sector has outperformed the market, with the pharmaceutical index rising by 22.09% compared to a 17.62% increase in the CSI 300 index, resulting in a 4.47 percentage point outperformance [11] - The chemical preparation sector showed the best performance, increasing by 40.52%, followed by medical services (+36.98%) and chemical raw materials (+25.34%) [20] - The overall PE valuation of the pharmaceutical sector is at 30.89 times, which is relatively low compared to historical averages, indicating potential for future growth [22][23] Innovative Drugs - The report notes that the growth of health expenditures in China, which reached 9.06 trillion yuan in 2023, is outpacing GDP growth, indicating a robust market for innovative drugs [26][27] - The analysis of multinational corporations (MNCs) reveals that innovation is a core competitive advantage, with companies like Eli Lilly and Novartis showing significant growth driven by innovative products in advanced technology fields such as GLP-1 and ADC [31][32] - The report highlights the strong sales performance of GLP-1 drugs, with Eli Lilly's Mounjaro generating $6.515 billion in revenue in Q3 2025, reflecting a 109% year-on-year increase [44] CXO and Upstream - The report indicates a slight increase in pharmaceutical financing, with a recovery in business development transactions and H-share IPOs, which is expected to stimulate innovation [5] - The demand for external CXO services is growing, particularly in emerging fields such as peptides and small nucleic acids, while internal CXO orders are also showing signs of recovery [5][39] Medical Devices - The domestic medical device market is currently under pressure due to policy impacts, but improvements are anticipated as companies continue to innovate and expand internationally [5] - The report suggests that the industry fundamentals are expected to improve, with a focus on companies like Mindray Medical and Microelectrophysiology [5][39]

Investment Rating - The industry investment rating is "Outperform the Market" [8] Core Viewpoints - The approval of the first batch of L3 conditional autonomous driving vehicle licenses by the Ministry of Industry and Information Technology marks a significant step towards the commercialization of L3 autonomous driving in China [2][3] - The current L3 vehicles have operational limitations, with one model capable of operating at a maximum speed of 50 km/h in congested traffic and another at 80 km/h on highways, but both are restricted to specific areas [3] - The commercialization of intelligent driving is expected to accelerate by 2026, with various companies planning to launch autonomous driving models and services during that year [3] Summary by Sections Industry Overview - The report highlights the transition of L3 autonomous driving technology from testing to commercial application, as indicated by the recent approvals [2][3] Regulatory Developments - The Ministry of Industry and Information Technology's approval signifies a policy advancement that supports the production of L3 vehicles, laying the groundwork for future commercialization [3] Market Opportunities - The report anticipates a key opportunity period for intelligent driving in 2026, with advancements in algorithms and the rollout of Robotaxi services [3] Investment Recommendations - Recommended companies include Horizon Robotics, Seres (Huawei ADS-enabled vehicles), Li Auto, Great Wall Motors, and Xpeng Motors, as they are positioned to benefit from the upcoming developments in the autonomous driving sector [3]

Investment Rating - The industry investment rating is "Outperform the Market" (预计6个月内，行业指数表现强于市场表现5%以上) [34] Core Insights - The report emphasizes the achievements of the medical insurance system during the "14th Five-Year Plan" period and outlines the key focus areas for 2026, including enhancing the basic medical insurance system, supporting the development of commercial health insurance, and optimizing medical insurance payment mechanisms [4][18] - The report suggests that the rise of innovative drugs is sustainable, recommending attention to companies with rich pipeline layouts, high-potential innovative drugs, and leading enterprises in cutting-edge technology platforms [6] Summary by Sections Industry Overview - The national medical insurance work conference was held in Beijing, focusing on the implementation of policies and strategies to improve the medical insurance system and support the development of the pharmaceutical industry [4][18] Investment Strategy - Investment recommendations include focusing on innovative drug companies with diverse pipelines, companies with high potential single products, and firms leading in advanced technology platforms [6] - The report also highlights the stability of R&D investments in the pharmaceutical sector and the potential for growth in emerging fields [6] Market Performance - The pharmaceutical sector experienced a decline of 1.04% last week, ranking 17th among 28 industries, while the Shanghai and Shenzhen 300 Index fell by 0.08% [9][20] - The valuation of the pharmaceutical sector is reported at 29.16 times (TTM), with a premium of 16.73% compared to the overall A-shares [25] Notable Industry News - Fosun Pharma licensed oral GLP-1 to Pfizer, with potential milestone payments totaling up to $15.85 billion based on sales performance [14] - Baiaosaitu successfully listed on the STAR Market, raising 1.267 billion yuan with a significant opening price increase [15] - Zhenjiang Tianqing's semaglutide injection application has been accepted for listing, indicating strong market interest in GLP-1 products [17]

Investment Rating - Industry investment rating: Outperform the market (expected to outperform the market by more than 5% in the next 6 months) [42] Core Insights - The development of commercial aerospace is accelerating, with a promising outlook for space computing capabilities. The continuous improvement in rocket technology and the increasing number of private rocket companies have led to a decrease in launch costs in China, with the cost per kilogram dropping from 115,000 RMB in 2020 to 75,000 RMB in 2024. It is expected to further decrease to 45,000 RMB by 2029 [6][3] - In 2024, China is projected to successfully launch rockets 68 times, with 74 launches already completed from January to November 2025, indicating a significant increase in launch activities [3][11] - The global space computing market is expected to grow significantly, with the market size projected to reach 2.8 billion USD by 2029, driven by advancements in satellite technology and AI applications in space [26][3] Summary by Sections Industry Dynamics - The cost of satellite launches in China has been decreasing annually, with a forecasted drop to 45,000 RMB per kilogram by 2029 [6] - The Chinese satellite market is expected to grow from 82.7 billion RMB in 2024 to 266.1 billion RMB by 2029, with a CAGR of 26.3% [17] - The deployment of computing clusters in space shows a significant cost advantage over ground-based systems, with a ten-year operational cost of 8.2 million USD in space compared to 167 million USD on the ground [22][23] Market Performance - The semiconductor industry index increased by 2.68% this week, outperforming the CSI 300 index by 2.76 percentage points. Since the beginning of 2024, the semiconductor index has risen by 80.19%, surpassing the CSI 300 index by 46.68 percentage points [32][30] - The overall P/E ratio for the semiconductor industry is 96.3 times, with 106 out of 168 A-share stocks in the sector experiencing price increases this week [36]

Investment Rating - The report maintains an "Outperform" rating for the industry [1] Core Insights - The establishment of a silicon material storage platform company is seen as a significant step towards addressing the "involution" competition in the photovoltaic industry [5][28] - The development of deep-sea wind power in Guangdong is expected to accelerate, with the establishment of Shenzhen Energy's marine energy company indicating progress in offshore wind project development [5][10] Summary by Sections Wind Power - The establishment of Shenzhen Energy's marine energy company aims to develop 3-5 offshore wind projects in Guangdong, signaling a boost in the region's offshore wind development [5][10] - The wind power index increased by 1.35%, outperforming the CSI 300 index by 1.42 percentage points, with a current PE_TTM valuation of approximately 25.32 times [4][11] Photovoltaics - The newly formed Beijing Guanghe Qiancheng Technology Co., Ltd. has a registered capital of 30 billion yuan, marking the launch of a long-anticipated "polysilicon capacity integration acquisition platform" [5][28] - The establishment of this platform is viewed as a key measure to mitigate the competitive pressures within the photovoltaic sector [5][28] Energy Storage & Hydrogen Energy - Energy storage facilities have been included in the REITs project list, providing a new exit strategy for operators and addressing the challenges of large investment scales and long recovery periods [6] - The report recommends investments in domestic and international large-scale storage, highlighting companies like Sungrow Power Supply and Shanghai Electric Power Equipment [6]

Investment Rating - The industry investment rating is "Outperform the Market" [9] Core Viewpoints - The report indicates that the inventory of unsold properties continues to decrease, and the month-on-month decline in new construction and completions is narrowing, suggesting a gradual stabilization in the real estate market [6][4] - The report highlights that while there are short-term fluctuations in sales, the overall trend is moving towards stabilization, with key actions needed to enhance rental returns and accelerate inventory reduction [6][4] Summary by Sections Sales and Inventory - In November, the national sales area of commercial housing decreased by 17.3% year-on-year, with sales amount dropping by 25.1%. The decline in sales area and amount has narrowed compared to October [6] - As of the end of November, the unsold housing inventory stood at 750 million square meters, marking a continuous reduction for nine months, indicating effective inventory clearance [6] Investment and Construction - National real estate investment in November fell by 30.3% year-on-year, with new construction down by 27.6% and completions down by 25.5%. However, the month-on-month decline in new construction has narrowed compared to October [6] - The report notes that funding for real estate development has decreased by 32.5% year-on-year, with domestic loans down by 10.4% and personal mortgage loans down by 34.7% [6] Future Outlook - The report anticipates that sales will remain under pressure in Q1 2026 due to high base effects, but improvements are expected in the second half of 2026 as various positive factors converge [6] - It suggests focusing on companies with optimized inventory structures and strong land acquisition capabilities, such as China Resources Land and Jianfa International, which are likely to benefit from the "good housing" initiative [6]

Investment Rating - The industry investment rating is "Outperform the Market," indicating an expected performance that exceeds the CSI 300 index by more than 5% over the next six months [38]. Core Insights - The report highlights the importance of balancing short-term and long-term economic policies, emphasizing the need for proactive macroeconomic measures to stimulate domestic demand and optimize supply [4][13]. - The Central Economic Work Conference introduced a new policy direction focusing on the integration of existing and new policies, aiming for coordinated and effective economic governance [13]. - The financial statistics for November show a robust monetary environment, with social financing and M2 growth rates remaining above 8%, supporting high-quality economic development [5][18]. Summary by Sections Key Focus Areas - The Central Political Bureau meeting on December 8 discussed strategies for 2026 economic work, emphasizing the need for a proactive macroeconomic policy and the importance of domestic demand [4][11]. - The Central Economic Work Conference held on December 10-11 reiterated the commitment to a proactive fiscal policy and moderately loose monetary policy, with a focus on enhancing the effectiveness of macroeconomic governance [13]. Financial Data - As of November, the new RMB loans increased by 390 billion yuan, with a year-on-year growth rate of 6.4%. The social financing scale increased by 2.49 trillion yuan, with a year-on-year growth rate of 8.5% [16][18]. - The M2 growth rate was 8.0%, reflecting a slight decrease from the previous month, indicating a stable monetary policy environment [18]. Market Performance - The banking, securities, insurance, and fintech indices experienced changes of -1.77%, +0.31%, +2.36%, and -0.92% respectively, with the CSI 300 index declining by 0.08% during the same period [19]. - The average daily trading volume for stock funds reached 23.943 trillion yuan, marking a 15.1% increase from the previous week [27][28].